GRID/CPCA: A new computational tool to design selective ligands

被引:161
作者
Kastenholz, MA
Pastor, M
Cruciani, G
Haaksma, EEJ
Fox, T [1 ]
机构
[1] Boehringer Ingelheim Pharma KG, Dept Chem Res Struct Res, D-88397 Biberach, Germany
[2] Univ Perugia, Lab Chemometr, I-06123 Perugia, Italy
关键词
D O I
10.1021/jm000934y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We present a computational procedure aimed at understanding enzyme selectivity and guiding the design of drugs with respect to selectivity. It starts from a set of 3D structures of the target proteins characterized by the program GRID. In the multivariate description proposed, the variables are organized and scaled in a different way than previously published methodologies. Then, consensus principal component analysis (CPCA) is used to analyze the GRID descriptors, allowing the straightforward identification of possible modifications in the ligand to improve its selectivity toward a chosen target. As an important new feature the computational method is able to work with more than two target proteins and with several 3D structures for each protein. Additionally, the use of a 'cutout tool' allows to focus on the important regions around the active site. The method is validated for a total number of nine structures of the three homologous serine proteases thrombin, trypsin, and factor Xa. The regions identified by the method as being important for selectivity are in excellent agreement with available experimental data and inhibitor structure-activity relationships.
引用
收藏
页码:3033 / 3044
页数:12
相关论文
共 60 条
[1]   Factor Xa inhibitors by classical and combinatorial chemistry [J].
Al-Obeidi, F ;
Ostrem, JA .
DRUG DISCOVERY TODAY, 1998, 3 (05) :223-231
[2]   Molecular recognition of protein-ligand complexes: Applications to drug design [J].
Babine, RE ;
Bender, SL .
CHEMICAL REVIEWS, 1997, 97 (05) :1359-1472
[3]   Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors [J].
Becker, MR ;
Ewing, WR ;
Davis, RS ;
Pauls, HW ;
Ly, C ;
Li, AW ;
Mason, HJ ;
Choi-Sledeski, YM ;
Spada, AP ;
Chu, V ;
Brown, KD ;
Colussi, DJ ;
Leadley, RJ ;
Bentley, R ;
Bostwick, J ;
Kasiewski, C ;
Morgan, S .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (18) :2753-2758
[4]   Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa [J].
Böhm, M ;
Stürzebecher, J ;
Klebe, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (03) :458-477
[5]   Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes [J].
Bone, R ;
Lu, TB ;
Illig, CR ;
Soll, RM ;
Spurlino, JC .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (12) :2068-2075
[6]   NEW HYDROGEN-BOND POTENTIALS FOR USE IN DETERMINING ENERGETICALLY FAVORABLE BINDING-SITES ON MOLECULES OF KNOWN STRUCTURE [J].
BOOBBYER, DNA ;
GOODFORD, PJ ;
MCWHINNIE, PM ;
WADE, RC .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (05) :1083-1094
[7]   X-ray structure of active site-inhibited clotting factor Xa - Implications for drug design and substrate recognition [J].
Brandstetter, H ;
Kuhne, A ;
Bode, W ;
Huber, R ;
vonderSaal, W ;
Wirthensohn, K ;
Engh, RA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (47) :29988-29992
[8]   Comparative molecular field analysis and energy interaction studies of thrombin-inhibitor complexes [J].
Bursi, R ;
Grootenhuis, PDJ .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1999, 13 (03) :221-232
[9]   Sulfonamidopyrrolidinone factor Xa inhibitors: Potency and selectivity enhancements via P-1 and P-4 optimization [J].
Choi-Sledeski, YM ;
McGarry, DG ;
Green, DM ;
Mason, HJ ;
Becker, MR ;
Davis, RS ;
Ewing, WR ;
Dankulich, WP ;
Manetta, VE ;
Morris, RL ;
Spada, AP ;
Cheney, DL ;
Brown, KD ;
Colussi, DJ ;
Chu, V ;
Heran, CL ;
Morgan, SR ;
Bentley, RG ;
Leadley, RJ ;
Maignan, S ;
Guilloteau, JP ;
Dunwiddie, CT ;
Pauls, HW .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (18) :3572-3587
[10]  
CLAESON G, 1993, DESIGN SYNTHETIC INH